Skip to main content
SpringerLink
Log in

High-Energy Phosphate Metabolism in Normal, Hypertrophied and Failing Human Myocardium

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

This chapter examines the role of cardiac high-energy phosphate metabolism in normal, hypertrophied and failing human myocardium. Myocardial biopsies allow analysis of ATP, total adenine nucleotides, creatine kinase activity and total creatine content, while non-invasive 31P-magnetic resonance spectroscopy can be used to determine phosphocreatine/ATP ratios and, most recently, absolute levels of ATP and phosphocreatine. The failing human myocardium is characterized by reduced phosphocreatine and total creatine levels, normal or slightly reduced ATP levels and reduced creatine kinase activity. These changes are consistent with, but do not prove, a role of high-energy phosphate metabolism as a contributing factor in heart failure. An answer to the precise functional role of high-energy phosphate metabolism necessitates analysis of free ADP levels, free energy change of ATP hydrolysis and creatine kinase reaction velocity; these measurements may become feasible in coming years. However, analysis of energy metabolism in a compartmentalized manner, i.e., in the compartments relevant for contractile function such as the perimyofibrillar space, will remain elusive for the foreseeable future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ingwall JS. Is cardiac failure a consequence of decreased energy reserve? Circulation 1993;87(Suppl VII):58–62.

    Google Scholar 

  2. Clarke K, O'Connor AJ, Willis RJ. Temporal relation between energy metabolism and myocardial function during ischemia and reperfusion. Am J Physiol 1987;253:H412–421.

    Google Scholar 

  3. Swain JL, Sabina RL, Peyton RB, Jones RN, Wechsler AS, Holmes EW. Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy. Proc Natl Acad Sci USA 1982;79:655–659.

    Google Scholar 

  4. Peyton RB, Jones RN, Attarian D, Sink JD, van Trigt P, Currie WD, Wechsler AS. Depressed high-energy phosphate content in hypertrophied ventricles of animal and man. Ann Surg 1982;196:278–284.

    Google Scholar 

  5. Starling RC, Hammer DF, Altschuld RA. Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem 1998;180:171–177.

    Google Scholar 

  6. Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol 1987;9: 734–742.

    Google Scholar 

  7. Regitz V, Fleck E. Myocardial adenine nucleotide concentrations and myocardial norepinephrine content in patients with heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol 1992;69:1574–1580.

    Google Scholar 

  8. Neubauer S, Ingwall JS. Verapamil attenuates ATP depletion during hypoxia: 31P NMR studies of the isolated rat heart. J Mol Cell Cardiol 1989;21:1163–1178.

    Google Scholar 

  9. Kammermeier H. Microassay of free and total creatine from tissue extracts by combination of chromatographic and fluorometric methods. Anal Biochem 1973;56:341–345.

    Google Scholar 

  10. Horn M, Frantz S, Remkes H, Laser A, Urban B, Metten-Neubauer leiter A, Schnackerz K, Neubauer S. Effects of chronic dietary creatine feeding on cardiac energy metabolism and on creatine content in heart, skeletal muscle, brain, liver and kidney. J Mol Cell Cardiol 1998;30:277–284.

    Google Scholar 

  11. Neubauer S, Hamman BL, Perry SB, Bittl JA, Ingwall JS. Velocity of the creatine kinase reaction decreases in postischemic myocardium: A 31P-NMR magnetization transfer study of the isolated ferret heart. Circ Res 1988;63:1–15.

    Google Scholar 

  12. Neubauer S, Frank M, Hu K, Remkes H, Laser A, Horn M, Ertl G, Lohse MJ. Changes of creatine kinase gene expression in residual intact myocardium of chronically infarcted rats. J Mol Cell Cardiol 1998;30:803–810.

    Google Scholar 

  13. Hoang CD, Zhang J, Payne RM, Apple FS. Post-infarction left ventricular remodeling induces changes in creatine kinase mRNA and protein subunit levels in porcine myocardium. Am J Pathol 1997;151(1):257–264.

    Google Scholar 

  14. Lowry OH, Rosebrough MJ, Farr AL, Randall RJ. Protein measurement with the foline reagent. J Biol Chem 1951; 193:265.

    Google Scholar 

  15. Bottomley PA. MR spectroscopy of the human heart: the status and the challenges. Radiology 1994;191:593–612.

    Google Scholar 

  16. von Kienlin M, Mejia R. Spectral localization with optimal pointspread function. Magn Reson Med 1991;94:268–287.

    Google Scholar 

  17. Meininger M, Landschütz W, Beer M, Seyfarth T, Horn M, Pabst T, Haase A, Hahn D, Neubauer S, von Kienlin M. Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. MRM 1999;41:657–663.

    Google Scholar 

  18. Hetherington HP, Luney DJ, Vaughan JT, Pan JW, Ponder SL, Tschendel O, Twieg DB, Pohost GM. 3D 31P spectroscopic imaging of the human heart at 4.1 T. Magn Reson Med 1995;33:427–431.

    Google Scholar 

  19. Menon RS, Hendrich K. 31P NMR spectroscopy of human heart at 4T: Detection of substantially uncontaminated cardiac spectra and differentiation of subepicardium and subendocardium. Magn Reson Med 1992;26:368–376.

    Google Scholar 

  20. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, Pessina AC, Allen PD. The creatine kinase system in failing and nonfailing human myocardium. Circulation 1996;94:1894–1901.

    Google Scholar 

  21. Auffermann W, Chew WM, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB. Normal and diffusely abnormal myocardium in humans: Functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 1991;179: 253–259.

    Google Scholar 

  22. Bottomley PA, Hardy CJ, Roemer PB. Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance. Magn Reson Med 1990;14:425–434.

    Google Scholar 

  23. Bottomley PA, Atalar E, Weiss RG. Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med 1996;35:664–670.

    Google Scholar 

  24. Neubauer S, Krahe T, Schindler R, Hillenbrand H, Entzeroth C, Horn M, Bauer WR, Stephan T, Lackner K, Haase A, et al. Direct measurement of spin-lattice relaxation times of phosphorus metabolites in human myocardium [see comments]. Magn Reson Med 1992;26:300–307.

    Google Scholar 

  25. van Dobbenburgh JO, Lekkerkerk C, van Echteld CJ, de Beer R. Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T. NMR Biomed 1994;7:218–224.

    Google Scholar 

  26. Hardy CJ, Bottomley PA, Rohling KW, Roemer PB. An NMR phased array for human cardiac 31P spectroscopy. Magn Reson Med 1992;28:54–64.

    Google Scholar 

  27. Bottomley PA, Hardy CJ. Mapping creatine kinase reaction rates in human brain and heart with 4 tesla saturation transfer 31P NMR. J Magn Reson 1992;99:443–448.

    Google Scholar 

  28. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 1985;313:1050–1054.

    Google Scholar 

  29. Bottomley PA, Weiss RG. Non-invasivemagnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 1998;351:714–718.

    Google Scholar 

  30. Balaban RS, Kantor HL, Katz LA, Briggs RW. Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science 1986;232:1121–1123.

    Google Scholar 

  31. Lamb HJ, Beyerbacht HP, R. O, Doornbos J, B.M. P, van der Wall EE, van der Laarse A, de Roos A. Metabolic response of normal human myocardium to high-dose atropine-dobutamine stress studied by 31P-MRS. Circulation 1997;96: 2969–2977.

    Google Scholar 

  32. Okada M, K. M, Inubushi T, Kinoshita M. Influence of aging or left ventricular hypertrophy on the human heart: Contents of phosphorus metabolites measured by 31P MRS. MRM 1998;39:772–782.

    Google Scholar 

  33. Lamb HJ, Beyerbacht HP, van der Laarse A, Stoel BC, Doornbos J, van derWall EE, de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999;99:2261–2267.

    Google Scholar 

  34. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine toATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991;338:973–976.

    Google Scholar 

  35. Neubauer S, Horn M, Pabst T, Harre K, Strömer H, Bertsch G, Sandstede J, Ertl G, Hahn D, Kochsiek K. Cardiac highenergy phosphate metabolism in patients with aortic valve disease assessed by 31P-magnetic resonance spectroscopy. J Invest Med 1997;45:453–462.

    Google Scholar 

  36. Conway MA, Bottomley PA, Ouwerkerk R, Radda GK, Rajagopalan B. Mitral regurgitation: Impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 1998;97:1716–1723.

    Google Scholar 

  37. Zhang J, Merkle H, Hendrich K, Garwood M, From AH, Ugurbil K, Bache RJ. Bioenergetic abnormalities associated with severe left ventricular hypertrophy. J Clin Invest 1993;92:993–1003.

    Google Scholar 

  38. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. New Engl J Med 1997;336/11:775–785.

    Google Scholar 

  39. Spindler M, Saupe KW, Christe ME, Seidman CE, Seidman JG, Ingwall JS. A murine model of familial hypertrophic cardiomyopathy shows a markedly impaired response to inotropic stimulation. Circulation 1996;94/8(Suppl I):I–433 (Abstract).

    Google Scholar 

  40. Rajagopalan B, Blackledge MJ, McKenna WJ, Bolas N, Radda GK. Measurement of phosphocreatine to ATP ratio in normal and diseased human heart by 31P magnetic resonance spectroscopy using the rotating frame-depth selection technique. Ann NY Acad Sci 1987;508:321–332.

    Google Scholar 

  41. Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G. Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease [see comments]. N Engl J Med 1990;323:1593–1600.

    Google Scholar 

  42. Masuda Y, Tateno Y, Ikehira H, Hashimoto T, Shishido F, Sekiya M, Imazeki Y, Imai H, Watanabe S, Inagaki Y. Highenergy phosphate metabolism of the myocardium in normal Energy Metabolism in Human Heart Failure subjects and patients with various cardiomyopathies—the study using ECG gated MR spectroscopy with a localization technique. Jpn Circ J 1992;56:620–626.

    Google Scholar 

  43. de Roos A, Doornbos J, Luyten PR, Oosterwaal LJ, van der Wall EE, den Hollander JA. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: Assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging 1992;2:711–719.

    Google Scholar 

  44. Sakuma H, Takeda K, Tagami T, Nakagawa T, Okamoto S, Konishi T, Nakano T. 31P MR spectroscopy in hypertrophic cardiomyopathy: Comparison with T1-201myocardial perfusion imaging. Am Heart J 1993;125:1323–1328.

    Google Scholar 

  45. Sieverding L, Jung WI, Breuer J, Widmaier S, Staubert A, van Erckelens F, Schmidt O, Bunse M, Hoess T, Lutz O, Dietze GJ, Apitz J. Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. Am J Cardiol 1997;80(3A):34A–40A.

    Google Scholar 

  46. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998;97:2536–2542.

    Google Scholar 

  47. Pluim BM, Chin JC, De Roos A, Doornbos J, Siebelink HM, Van der Laarse A, Vliegen HW, Lamerichs RM, Bruschke AV, Van der Wall EE. Cardiac anatomy, function and metabolism in elite cyclists assessed by magnetic resonance imaging and spectroscopy [see comments]. Eur Heart J 1996;17:1271–1278.

    Google Scholar 

  48. Pluim BM, Lamb HJ, Kayser HW, Leujes F, Beyerbacht HP, Zwinderman AH, van der Laarse A, Vliegen HW, de Roos A, van der Wall EE. Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circulation 1998;97:666–672.

    Google Scholar 

  49. Spencer RG, Buttrick PM, Ingwall JS. Function and bioenergetics in isolated perfused trained rat hearts. Am J Physiol 1997;272:H409–417.

    Google Scholar 

  50. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991;122:795–801.

    Google Scholar 

  51. Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B. In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol 1990;65:1154–1161.

    Google Scholar 

  52. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphatemetabolism in heart failure. Circulation 1992;86:1810–1818.

    Google Scholar 

  53. Neubauer S, Horn M, Pabst T, Gödde M, Lübke D, Illing B, Hahn D, Ertl G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 1995;16 (Suppl O):115–118.

    Google Scholar 

  54. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. In patients with dilated cardiomyopathy the myocardial phosphocreatine-to-ATP ratio is a predictor of mortality. Circulation 1997;96:2190–2196.

    Google Scholar 

  55. Meininger M, Landschütz W, Beer M, Seyfarth T, Bertsch G, Sandstede J, Pabst T, Horn M, Haase A, Hahn D, von Kienlin M, Neubauer S. Nichtinvasive Messung der Absolutkonzentrationen der energiereichen Phosphate am gesunden und insuf~zienten menschlichen Myokard mit 31P-SLOOPMRS. Z Kardiol 1999;88:278 (Abstract).

    Google Scholar 

  56. Cohn J, Bristow MR, Chien KR, Colucci WS, Frazier H, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Leinrib L. Report of the national heart, lung, and blood institute special emphasis panel on heart failure research. Circulation 1997;95:766–770.

    Google Scholar 

  57. Blackledge MJ, Rajagopalan B, Oberhaensli RD, Bolas NM, Styles P, Radda GK. Quantitative studies of human cardiac metabolism by 31P rotating-frame NMR. Proc Natl Acad Sci USA 1987;84:4283–4287.

    Google Scholar 

  58. Schaefer S, Gober J, Valenza M, Karczmar GS, Matson GB, Camacho SA, Botvinick EH, Massie B, Weiner MW. Nuclear magnetic resonance imaging-guided phosphorus-31 spectroscopy of the human heart. J Am Coll Cardiol 1988;12:1449–1455.

    Google Scholar 

  59. Yabe T, Mitsunami K, Okada M, Morikawa S, Inubushi T, Kinoshita M. Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise. Circulation 1994;89:1709–1716.

    Google Scholar 

  60. Yabe T, Mitsunami K, Inubushi T, Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy [see comments]. Circulation 1995;92:15–23.

    Google Scholar 

  61. Kalil-Filho R, de Albuquerque CP, Weiss RG, Mocelim A, Bellotti G, Cerri G, Pileggi F. Normal high-energy phosphate ratios in stunned human myocardium. J Am Coll Cardiol 1997;30:1228–1232.

    Google Scholar 

  62. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190–2196.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Universitätsklinik, Germany s

    Stefan Neubauer

Authors
  1. Stefan Neubauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neubauer, S. High-Energy Phosphate Metabolism in Normal, Hypertrophied and Failing Human Myocardium. Heart Fail Rev 4, 269–280 (1999). https://doi.org/10.1023/A:1009866108384

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009866108384

Search

Navigation